Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
AC Immune SA ( (ACIU) ) has shared an announcement.
AC Immune SA announced positive interim safety data from its Phase 1b/2 ABATE trial of ACI-24.060 for individuals with Down syndrome, highlighting the therapy’s safety and tolerability. The findings are promising as no serious adverse events or amyloid-related imaging abnormalities were observed, encouraging the expansion to a high-dose cohort. The trial aims to address the early stages of Alzheimer’s disease in this population, with ongoing recruitment in the U.S., U.K., and Spain.
More about AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, utilizing its SupraAntigen® and Morphomer® platforms. The company is recognized for its extensive pipeline of therapeutic and diagnostic programs and strategic partnerships with leading pharmaceutical firms.
YTD Price Performance: -37.20%
Average Trading Volume: 113,182
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $313M
For an in-depth examination of ACIU stock, go to TipRanks’ Stock Analysis page.
